受强制性开放获取政策约束的文章 - Robert G Maki, MD PhD了解详情
可在其他位置公开访问的文章：110 篇
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
强制性开放获取政策： US National Institutes of Health
A framework for advancing our understanding of cancer-associated fibroblasts
E Sahai, I Astsaturov, E Cukierman, DG DeNardo, M Egeblad, RM Evans, ...
Nature Reviews Cancer 20 (3), 174-186, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health, German Research …
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
RP DeMatteo, KV Ballman, CR Antonescu, RG Maki, PWT Pisters, ...
The lancet 373 (9669), 1097-1104, 2009
强制性开放获取政策： US National Institutes of Health
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …
GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ...
The Lancet 381 (9863), 295-302, 2013
强制性开放获取政策： US National Institutes of Health
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
GD Demetri, M Von Mehren, CR Antonescu, RP DeMatteo, KN Ganjoo, ...
Journal of the National Comprehensive Cancer Network 8 (Suppl_2), S-1-S-41, 2010
强制性开放获取政策： US National Institutes of Health
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ...
The Lancet Oncology 18 (11), 1493-1501, 2017
强制性开放获取政策： US National Institutes of Health
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
强制性开放获取政策： US National Institutes of Health
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
MC Heinrich, RG Maki, CL Corless, CR Antonescu, A Harlow, D Griffith, ...
Journal of clinical oncology 26 (33), 5352-5359, 2008
强制性开放获取政策： US National Institutes of Health
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ...
New England Journal of Medicine 363 (18), 1727-1733, 2010
强制性开放获取政策： US National Institutes of Health
Comprehensive and integrated genomic characterization of adult soft tissue sarcomas
AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ...
Cell 171 (4), 950-965, 2017
强制性开放获取政策： US National Institutes of Health
Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized …
GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ...
Journal of Clinical Oncology 34 (8), 786-793, 2016
强制性开放获取政策： US National Institutes of Health
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
J Barretina, BS Taylor, S Banerji, AH Ramos, M Lagos-Quintana, ...
Nature genetics 42 (8), 715-721, 2010
强制性开放获取政策： US National Institutes of Health
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
RG Maki, DR D'Adamo, ML Keohan, M Saulle, SM Schuetze, SD Undevia, ...
Journal of Clinical Oncology 27 (19), 3133-3140, 2009
强制性开放获取政策： US National Institutes of Health
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a …
JS Gold, M Gönen, A Gutiérrez, JM Broto, X García-del-Muro, TC Smyrk, ...
The lancet oncology 10 (11), 1045-1052, 2009
强制性开放获取政策： US National Institutes of Health
A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites
C Errani, L Zhang, YS Sung, M Hajdu, S Singer, RG Maki, JH Healey, ...
Genes, Chromosomes and Cancer 50 (8), 644-653, 2011
强制性开放获取政策： US National Institutes of Health
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with …
SHI Ou, EL Kwak, C Siwak-Tapp, J Dy, K Bergethon, JW Clark, ...
Journal of thoracic oncology 6 (5), 942-946, 2011
强制性开放获取政策： US National Institutes of Health
Advances in sarcoma genomics and new therapeutic targets
BS Taylor, J Barretina, RG Maki, CR Antonescu, S Singer, M Ladanyi
Nature Reviews Cancer 11 (8), 541-557, 2011
强制性开放获取政策： US National Institutes of Health
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ...
Journal of clinical oncology 28 (5), 835-840, 2010
强制性开放获取政策： US National Institutes of Health
Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors
NP Agaram, GC Wong, T Guo, RG Maki, S Singer, RP DeMatteo, ...
Genes, Chromosomes and Cancer 47 (10), 853-859, 2008
强制性开放获取政策： US National Institutes of Health
Sorafenib for advanced and refractory desmoid tumors
MM Gounder, MR Mahoney, BA Van Tine, V Ravi, S Attia, HA Deshpande, ...
New England Journal of Medicine 379 (25), 2417-2428, 2018
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定